These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16705455)

  • 1. Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma.
    Rostagno C; Ciolli S
    Ann Hematol; 2006 Sep; 85(9):627-8. PubMed ID: 16705455
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
    Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
    Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
    [No Abstract]   [Full Text] [Related]  

  • 3. Myelomatous pleural effusion.
    Ghosh S; Gopal R; Advani SH
    J Assoc Physicians India; 2006 Sep; 54():738-9. PubMed ID: 17212026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 5. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
    Richardson P; Anderson K
    J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation.
    Witzens-Harig M; Waldherr R; Beimler J; Zeier M; Hansmann J; Ho AD; Goldschmidt H; Moehler T
    Ann Hematol; 2007 Dec; 86(12):927-30. PubMed ID: 17605010
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple myeloma presenting as plasmacytoma of the base of the skull.
    Alegre A; Tomás JF; Pinilla I; Gil-Fernández JJ; Fernández-Rañada JM
    Am J Hematol; 1996 May; 52(1):60-1. PubMed ID: 8638614
    [No Abstract]   [Full Text] [Related]  

  • 8. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E; Bloem AC; Sinnige HA; Lokhorst HM
    Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
    Lila AM; Mazurov VI; Novik AA
    Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578
    [No Abstract]   [Full Text] [Related]  

  • 10. An unusual case of pulmonary hypertension in a young male.
    Rostagno C; Ciolli S; Prisco D
    Intern Emerg Med; 2006; 1(2):127-32. PubMed ID: 17111785
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of multiple myeloma--associated amyloidosis by interferon-alpha, dimethyl sulfoxide, and VAD (vincristine, adriamycin, and dexamethasone).
    Ichida M; Imagawa S; Ohmine K; Komatsu N; Hatake K; Ozawa K; Miura Y
    Int J Hematol; 2000 Dec; 72(4):491-3. PubMed ID: 11197218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with VAD of a myelodysplastic syndrome occurring during the course of a smoldering multiple myeloma.
    Cortesão E; Espadana A; Laranjeiro P; Jara M; Orfão A
    Leuk Res; 2009 Jan; 33(1):195-7. PubMed ID: 18511113
    [No Abstract]   [Full Text] [Related]  

  • 15. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
    Jimenez-Zepeda VH; Domínguez-Martínez VJ
    Eur J Haematol; 2006 Sep; 77(3):239-44. PubMed ID: 16856924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bulbar palsy in multiple myeloma.
    Chim CS; Ooi GC
    Haematologica; 2005 Dec; 90(12 Suppl):ECR42. PubMed ID: 16464757
    [No Abstract]   [Full Text] [Related]  

  • 17. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
    van Rhee F
    Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
    [No Abstract]   [Full Text] [Related]  

  • 19. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
    Rajkumar SV
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
    [No Abstract]   [Full Text] [Related]  

  • 20. Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.
    Dasanu CA; Vaillant JG; Alexandrescu DT
    Dermatol Online J; 2006 Oct; 12(6):10. PubMed ID: 17083890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.